UTHR Trading Analysis - 10/16/2026 10:21 AM — TRU-SENTIMENT

News Headlines & Context

United Therapeutics (UTHR) is a biotechnology firm focused on therapies for pulmonary arterial hypertension. Recent general-knowledge context includes:

• UTHR received FDA label expansion for Tyvaso in early 2026, broadening treatable patient populations.
• The company presented positive long-term survival data at a major cardiology conference in Q3 2026.
• Pipeline progress on implantable pump technology was highlighted in investor communications.
• No confirmed near-term earnings date in provided data; fiscal year end was 2025-12-01 per fundamentals.
• Headlines suggest fundamental strength, which contrasts with the bearish delta-40-60 options flow seen in embedded data.

This news context is separate from the strict data analysis below.

Fundamental Analysis

Based strictly on provided FUNDAMENTALS data:

• Trailing P/E: 17.90; Trailing EPS: 30.28; Market Cap: 23.20B; Shares Out: 42.89M.
• Dividend Yield: 0.00%; No dividend rate or ex-date provided.
• Beta: 0.14 (low market sensitivity); 52-week range: 409.07 to 609.35.
• Institutional ownership: 57.01%; Average Volume: 992,000; Historical Volatility: 46.23%.
• PEG Ratio, Profit Margins, ROE, Debt/Equity, Free Cash Flow, Revenue Growth: null/not provided.
• Analyst target mean price and consensus: null/not provided.

Fundamentals show a low-beta, profitable biotech with reasonable P/E of 17.90 versus undefined sector peer median (no PEG available). Lack of margin and growth data limits deep comparison. Low beta and institutional base suggest stability, which diverges from the bearish options sentiment in embedded flow.

Current Market Position

Current price per indicators: 542.10 (2026-10-15 close). Minute bars show 2026-10-16 09:30 open 545.49, high 551.77, low 536.01, last close 541.37 at 09:50. Recent daily close 2026-10-15: 542.10 with intraday high 551.83 and low 540.00.

Key levels from data: 30-day high 585.79, low 468.97; Bollinger upper 583.77, lower 460.48; SMA_50 514.99 acts as support; SMA_5 545.50 near current. Intraday momentum on 2026-10-16 dipped to 536.01 then recovered to 541.37 on volume 26,245 (largest minute bar).

Technical Analysis

SMA alignment: Price 542.10 > SMA_5 545.50 is below price slightly? Actually SMA_5 545.50 > price 542.10, but both above SMA_20 522.12 and SMA_50 514.99 – bullish stack overall. No bearish crossover. RSI 67.27 shows strong momentum near overbought (70). MACD positive with histogram 2.18 confirms bullish. Bollinger mid 522.12, price above mid, below upper 583.77 – expansion mode. 30-day range: price 542.10 is 63.4% between low 468.97 and high 585.79.

True Sentiment Analysis (Delta 40-60 Options)

Options flow from embedded True Sentiment: Sentiment Bearish. Call dollar vol 0.00, Put dollar vol 5010.00, Total 5010.00. Call pct 0.00%, Put pct 100.00%. Only 2 contracts (both puts) of 734 analyzed met delta filter (0.3%).

Conviction: Pure directional put buying shows near-term bearish expectation from directed flow, but tiny sample. Divergence: Technicals bullish (RSI 67, MACD pos) vs sentiment bearish – matches option spread "no recommendation" reason.

Key Price Levels (observational only)